Cambridge, MA-based Stromedix, a startup formed around technology licensed from Biogen Idec (NASDAQ: [[ticker:BIIB]]), announced today that its lead candidate—a treatment for chronic allograft nephropathy, a leading cause of kidney-transplant failure—was granted orphan-drug status by the FDA. Stromedix is pursuing a large, untapped market for drugs that target fibrosis, a cellular process that is the ultimate cause of almost all types of organ failure. I profiled Stromedix’s intriguing strategy and corporate history in April.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
